| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 07/12/2005 | US6916941 Crystallization fromn solutions; antidepressant |
| 07/12/2005 | US6916872 Drug delivery; improved refractive index, transparency to light, reflection, permeability, coercivity, magnetic hystereisis, breakdown voltage, biocompatability, and wear resistance |
| 07/12/2005 | US6916857 Hydrogel-forming system with hydrophobic and hydrophilic components |
| 07/12/2005 | US6916824 Methods of treating cataracts and diabetic retinopathy with tricyclic pyrones |
| 07/12/2005 | US6916823 Method of treatment of dopamine-related dysfunction |
| 07/12/2005 | US6916794 Method of enhancing drainage of lacrimal system with purinergic receptor agonists |
| 07/12/2005 | US6916789 Synthetic polypeptide ligand for use in the treatment of cardiovascular, tumor, viral and hypertensive disorders |
| 07/12/2005 | US6916788 Liquid composition of biodegradable block copolymer for drug delivery system and process for the preparation thereof |
| 07/12/2005 | US6916785 Homogeneous cyclosporin-containing solution |
| 07/12/2005 | US6916490 Coacervate microsphere of polycationic and polyanionic molecules crosslinked by a crosslinked agent with a metal cation, a nucleic acid and a delivery agent |
| 07/12/2005 | US6916489 Active agent transport systems |
| 07/12/2005 | US6916488 Hollow capsules with membranes having hydrophobic and hydrophilic segments of block copolymers |
| 07/12/2005 | US6916487 Antiemetic, dermal penetration enhancer of a safe skin-tolerant sunscreen ester and volatile liquids |
| 07/12/2005 | US6916486 Mixture of analgesic hormones, skin penetration and sunscreen agents |
| 07/12/2005 | US6916485 Mixture of protein, hydrophilic polymer, group 1a alkyl sulfate and sugar |
| 07/12/2005 | US6916484 Sugars and sugar alcohols as isotonizing agents and has < 10 ppb of iron |
| 07/12/2005 | US6916483 Bioabsorbable plugs containing drugs |
| 07/12/2005 | US6916303 Photoreduction method for hemoglobin-vesicle |
| 07/12/2005 | US6915802 Medicament pack |
| 07/12/2005 | CA2303309C Synergistic analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor |
| 07/12/2005 | CA2298142C Soya extract, process for its preparation and pharmaceutical composition |
| 07/12/2005 | CA2245617C Ophthalmic solutions viscosified with tamarind seed polysaccharide |
| 07/12/2005 | CA2230947C Implantable controlled release device to deliver drugs directly to an internal portion of the body |
| 07/12/2005 | CA2165190C Dispenser containing hydrophobic agent |
| 07/12/2005 | CA2094494C A 4-quinolone antibiotic compound as gamma ray scintigraphy diagnostic imaging agent |
| 07/07/2005 | WO2005061552A1 Amphiphilic heparin derivative formed by coupling a heparin with a bile acid |
| 07/07/2005 | WO2005061095A1 Process for producing microsphere and apparatus for producing the same |
| 07/07/2005 | WO2005061090A1 Device, method and use for the formation of small particles |
| 07/07/2005 | WO2005061088A1 Powder formation by atmospheric spray-freeze drying |
| 07/07/2005 | WO2005061041A1 Insulin delivery system with sensor |
| 07/07/2005 | WO2005061004A1 Nanoparticle compositions of water-soluble drugs for oral administration and preparation methods thereof |
| 07/07/2005 | WO2005060983A1 Fluidizing bed processing garlic to reduce digestive after odors |
| 07/07/2005 | WO2005060981A2 Pharmaceutical compositions |
| 07/07/2005 | WO2005060953A1 Use of organic buffering agents to enhance the antimicrobial activity of pharmaceutical compositions |
| 07/07/2005 | WO2005060945A2 Intranasal compositions comprising zolpidem |
| 07/07/2005 | WO2005060944A1 Film-forming starchy composition |
| 07/07/2005 | WO2005060943A1 Antifungal oral dosage forms and the methods preparation |
| 07/07/2005 | WO2005060942A1 Extended release pharmaceutical composition of metformin |
| 07/07/2005 | WO2005060941A1 Extended release antibiotic composition |
| 07/07/2005 | WO2005060940A2 Method for the production of a solid, orally applicable pharmaceutical composition |
| 07/07/2005 | WO2005060939A2 Controlled-release pharmaceutical formulation |
| 07/07/2005 | WO2005060938A1 Process for producing pellets for pharmaceutical compositions |
| 07/07/2005 | WO2005060937A1 Compressed tablets comprising viable probiotic microorganisms |
| 07/07/2005 | WO2005060936A1 Cefdinir oral suspension |
| 07/07/2005 | WO2005060935A1 Drug-containing nanoparticle, process for producing the same and parenterally administered preparation from the nanoparticle |
| 07/07/2005 | WO2005060934A1 A novel cationic lipopolymer as a biocompatible gene delivery agent |
| 07/07/2005 | WO2005060933A1 Ophthalmic compositions containing a polysaccharide/borate gelling system |
| 07/07/2005 | WO2005060922A1 Cosmetic composition containing a polyorganosiloxane polymer |
| 07/07/2005 | WO2005060871A1 Pharmaceutical formulations of camptothecins and process for making same |
| 07/07/2005 | WO2005060550A2 Methods and compositions for treating skin wounds |
| 07/07/2005 | WO2005060540A2 Norethindrone sustained release transdermal formulation |
| 07/07/2005 | WO2005060361A2 Pharmaceutical formulations for itraconazole |
| 07/07/2005 | WO2005051483A3 Electrical devices and anti-scarring agents |
| 07/07/2005 | WO2005048911A3 Silicone products and methods for making silicone products |
| 07/07/2005 | WO2005046639A3 Modular imbibition rate reducer for use with implantable osmotic pump |
| 07/07/2005 | WO2005046637A3 Pharmaceutical formulations employing short-chain sphingolipids and their use |
| 07/07/2005 | WO2005037346A3 Method for providing long-lasting pain relief through intrathecal administration of civamide |
| 07/07/2005 | WO2005027768A3 Hydrogel compositions with an erodible backing member |
| 07/07/2005 | WO2005023304A3 Antimalarial compositions and manufacturing process thereof |
| 07/07/2005 | WO2005018582A3 Compositions containing topical active agents and pentylene glycol |
| 07/07/2005 | WO2005011586A3 Treatment and preventi0n of cardiovascular events |
| 07/07/2005 | WO2005007082A8 Treatment of chronic bacterial infection |
| 07/07/2005 | WO2005007080A3 Methods and compositions for delivery of catecholic butanes for treatment of tumors |
| 07/07/2005 | WO2005007074A3 Gellan gum based oral controlled release dosage forms- a novel platform technology for gastric retention |
| 07/07/2005 | WO2004105680A3 Oral care products comprising calcium metasilicates |
| 07/07/2005 | WO2004091500A3 Delivery of immune response modifier compounds |
| 07/07/2005 | WO2004073605A3 Skin peeling composition and method |
| 07/07/2005 | WO2004017914A8 Inhalation composition |
| 07/07/2005 | WO2004004779A8 Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine |
| 07/07/2005 | WO2003061571A3 Combination il-2/anti-herz antibody therapy for cancers characterized by overexpression of the her2 receptor protein |
| 07/07/2005 | US20050149157 Electrical devices and anti-scarring agents |
| 07/07/2005 | US20050149118 High strength suture with absorbable core and suture anchor combination |
| 07/07/2005 | US20050149000 Medical device with controlled reservoir opening |
| 07/07/2005 | US20050148664 therapy of NF-kappaB mediated diseases; mitochondrial diseases; transplantation medicine |
| 07/07/2005 | US20050148597 Controlled release of sterile freeze dried aripirazole in water for intramuscular injection |
| 07/07/2005 | US20050148594 Salt with choline, ethanolamine, diethanolamine, piperazine, calcium or tromethamine, optionally embedded in an enteric binder; recrystallization prevention; improved bioavailability and photostability |
| 07/07/2005 | US20050148582 N-[1-butyl-4-piperidinylmethyl[3,4-dihydro-2 oxazino[3,2-a indole-10 carboxamide as drugs with Cahpo4 or Ca3/po4/2 fillers or binders for use in treatment of irritable bowel syndrome, urinry incontience or arrhythmias |
| 07/07/2005 | US20050148563 Pulmonary disease treatment |
| 07/07/2005 | US20050148562 Pharmaceutical compositions based on anticholinergics and additional active ingredients |
| 07/07/2005 | US20050148557 Use of Vitamin Ds to treat kidney disease |
| 07/07/2005 | US20050148556 Compositions and methods for increasing HDL and HDL-2b levels |
| 07/07/2005 | US20050148542 Higher viscosity; reduced turbulence around tissues during eye surgery; preventing damage |
| 07/07/2005 | US20050148537 Immunostimulatory nucleic acid molecules |
| 07/07/2005 | US20050148528 Via antisense oligonucleotides that inhibit the expression of raf-1 gene, formulated in liposomes with enhanced penetration into cells; free of chemotherapy/radiation treatments |
| 07/07/2005 | US20050148497 Method for administering glp-1 molecules |
| 07/07/2005 | US20050148495 Using XMP.629 ( a peptide containing NH2-lys-leu-phe-arg-(1-naphthyl)-ala)-gln-ala-lys(3-naphthyl)-ala)CONH2 or a pharmaceutically acceptable salt or derivative as antiacne agent |
| 07/07/2005 | US20050148070 Propagating human progenitor cell using nutrient broth free of mammalian fetal serum; tissue engineering; regenerative medicine |
| 07/07/2005 | US20050147724 Use of multi-layer pigments in the food and pharmaceutical industry |
| 07/07/2005 | US20050147698 dietary supplements for ocular nutrition; comprise DHA (docosahexaenoic acid) |
| 07/07/2005 | US20050147690 Biocompatible purified proteins combined with biocompatible solvent(s) to form a cohesive body that is subsequently solidified and processed into particles; may also include drugs or adjuvants; biointegration and remodeling by host tissue; structural scaffold; moldability; mimetics; drug delivery |
| 07/07/2005 | US20050147689 Method for inhibiting the growth of gastrointestinal tract tumors |
| 07/07/2005 | US20050147688 Administering a stable, uniform, microfluidized nanosuspension of nanodroplets of a drug to a patient where it is absorhed into the bloodstream, particularly by the buccal mucosal route; bioavailability, enhanced period of onset, and enhanced stability for a controlled-release product |
| 07/07/2005 | US20050147687 Inducing a phase change, e.g. heating at a controlled rate, in a solution of alpha-1-antitrypsin (AAT), a phase separation promoter and a solvent to form particles and a liquid phase of the promoter and solvent; nano- and microspheres of 0.01-200 mu m; drug delivery; embryonic encapsulated particles |
| 07/07/2005 | US20050147685 10% Of a crosslinked, charge-possessing unsaturated monomer (carboxy, sulfonate, phosphate) and a neutral second monomer crosslinked to a lower degree than the first; highcompression; tensile strength; chemical resistance; flexibility; water-absorbing/retaining; industrial and biosubstitution materials |
| 07/07/2005 | US20050147684 A hematopoietic growth factor, a liquid vehicle, a first and second biocompatible polymers; exhibits reverse-thermal viscosity behavior due to interaction between the first polymer and vehicle; the second polymer forms a protective colloid; sustained delivery; increased half-life; side effect reduction |
| 07/07/2005 | US20050147683 A hematopoietic growth factor, a liquid vehicle, a first and second biocompatible polymers; exhibits reverse-thermal viscosity behavior due to interaction between the first polymer and vehicle; the second polymer forms a protective colloid; sustained delivery; increased half-life; side effect reduction |
| 07/07/2005 | US20050147682 A hematopoietic growth factor, a liquid vehicle, a first and second biocompatible polymers; exhibits reverse-thermal viscosity behavior due to interaction between the first polymer and vehicle; the second polymer forms a protective colloid; sustained delivery; increased half-life; side effect reduction |
| 07/07/2005 | US20050147680 Injectable veterinary composition for small animals |
| 07/07/2005 | US20050147678 Controlled release oral dosage form |
| 07/07/2005 | US20050147677 Using compression, thermal cycle molding, and thermal setting molding modules in continuous process |